1638 related articles for article (PubMed ID: 25867677)
1. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
4. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM
Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155
[TBL] [Abstract][Full Text] [Related]
5. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.
Tarawneh R; Lee JM; Ladenson JH; Morris JC; Holtzman DM
Neurology; 2012 Mar; 78(10):709-19. PubMed ID: 22357717
[TBL] [Abstract][Full Text] [Related]
6. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
[TBL] [Abstract][Full Text] [Related]
11. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
[TBL] [Abstract][Full Text] [Related]
13. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
15. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
[TBL] [Abstract][Full Text] [Related]
16. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
17. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
19. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
[TBL] [Abstract][Full Text] [Related]
20. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]